Nanotechnology in Healthcare: Getting Smaller and Smarter
We are living at the dawn of the nanomedicine age. I believe that nanoparticles and nanodevices will soon operate as precise drug delivery systems, cancer treatment tools or tiny surgeons. Let me introduce you the brave, new world of nanotechnology in healthcare. Nanorobots having nanobreakfast with your red and white blood cells When I was a kid, one of my favorite TV series was a French animation, Il était un fois… la vie (1986). I found it fascinating how the creators imagined the human body as a construction where tiny cars floated through the human veins, grab-cranes worked on teeth and bacteria as tiny monsters tried to attack innocent screaming lady-cells, while white blood cells defended the body as well-trained soldiers. Somehow similarly, the 1966 movie, Fantastic Voyage explored shrinking a medical team to microscopic size in order to save a renowned scientist’s life. The Argonauts travel through the bloodstream into the brain where the crew uses a laser gun to blast away a blood clot. Now, imagine that all this could happen in real life… How about a nanometer sized cage that lets out insulin but doesn’t get attacked by our immune system? How about a nanorobot delivering dopamine directly to the brainstem for treating Parkinson’s disease? And how about injecting chemotherapy into cancer cells while keeping healthy cells untouched? Could you imagine microscopic robots inside you sending alerts to your smartphone that a disease...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: Available online 9 October 2020Source: Mutation Research/Reviews in Mutation ResearchAuthor(s): Klaudia Kulczynska-Figurny, James J. Bieker, Miroslawa Siatecka
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
CONCLUSIONS: Immunohistochemistry seems to be a promising option not only in clinical recognition, but also in the selection and monitoring of treatment effects. However, these methods have not yet recommended for routine clinical use. PMID: 33032462 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
CONCLUSION: This study found that childhood cancer survivors in New Zealand had a high prevalence of developmental dental abnormalities and it identified potential risk factors related to their cancer treatment. Inequitable access to oral rehabilitation for this patient group argues for a mechanism for consistent improved access to publicly funded dental care across district health boards in New Zealand. PMID: 33032302 [PubMed - in process]
Authors: Zarrabi A, Mark S PMID: 33032299 [PubMed - in process]
More News: Academies | Anemia | Biotechnology | Bleeding | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Chemistry | Chemotherapy | Colon Cancer | Colorectal Cancer | Computers | Diabetes | Diabetes Type 1 | Endocrinology | Environmental Health | Geneticists and Genetics Commentators | Insulin | John Hopkins University | Laser Surgery | Legislation | Measles | Measles Vaccine | Medical Ethics | Molecular Biology | MRI Scan | Nanotechnology | Neurology | Neuroscience | Neurosurgery | Parkinson's Disease | PET Scan | Physics | Science | Skin | Skin Biopsy | Stem Cell Therapy | Stem Cells | Toxicology | Vaccines